Adaptive Biotechnologies Corp - 10-Q Filing

Adaptive Biotechnologies Corp reports Q3 2026 financial results featuring revenue from Sequencing, MRD, and Immune Medicine segments.

3 articles from 1 source · updated November 7, 2026, 00:25 UTC

Coverage

• Adaptive Biotechnologies Corp - 4 Filing SEC EDGAR · November 7, 2026, 00:25 UTC
• Canopy Growth Corp - 10-Q Filing SEC EDGAR · November 6, 2026, 11:45 UTC
• Adaptive Biotechnologies Corp - 10-Q Filing SEC EDGAR · November 4, 2026, 21:30 UTC